Ocular Therapeutix. has filed a patent for a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor in a hydrogel for long-term treatment of retinal diseases. The implant is compact and does not contain tyrosine kinase inhibitors in its dry state. GlobalData’s report on Ocular Therapeutix gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ocular Therapeutix Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ocular Therapeutix, Nanoparticle drug conjugates was a key innovation area identified from patents. Ocular Therapeutix's grant share as of January 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.

Ocular implant for retinal disease treatment with sustained release

Source: United States Patent and Trademark Office (USPTO). Credit: Ocular Therapeutix Inc

A recently filed patent (Publication Number: US20230390189A1) describes a sustained release biodegradable ocular implant designed to treat ocular diseases. The implant consists of a hydrogel with active agent particles dispersed within it, with a maximum length of 17 mm in its dry state. Notably, the active agent used in the implant is specified to not be a tyrosine kinase inhibitor, distinguishing it from other ocular treatments in the market.

The patent also outlines a method for treating ocular diseases by administering the sustained release biodegradable ocular implant to patients in need. This method involves the use of the hydrogel implant with active agent particles, as described in claim 1 of the patent. Additionally, the patent details a manufacturing process for the implant, which includes forming a hydrogel with a polymer network and dispersing active agent particles within it, shaping the hydrogel, and drying it to create the final product. These innovative methods and compositions described in the patent aim to provide a more effective and convenient treatment option for ocular diseases, potentially offering significant benefits to patients in need of such therapies.

To know more about GlobalData’s detailed insights on Ocular Therapeutix, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies